NCT02297594View on ClinicalTrials.gov

Safety, Tolerability and PK Study of AK0529 in Healthy Human

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

AK0529

AK0529 capsule for oral administration

DRUG

Placebo

Sugar placebo capsule for oral administration

Trial Locations (1)

4006

Q-Pharm Pty Ltd QIMR Berghofer & Royal Brisbane and Women's Hospital Campus, Brisbane

All Listed Sponsors
lead

Shanghai Ark Biopharmaceutical Co., Ltd.

INDUSTRY

NCT02297594 - Safety, Tolerability and PK Study of AK0529 in Healthy Human | Biotech Hunter | Biotech Hunter